ATHA Athira Pharma

Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

BOTHELL, Wash., Sept. 19, 2023 (GLOBE NEWSWIRE) --  (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in a panel presentation at the 2023 Cantor Fitzgerald Global Healthcare Conference taking place from September 26-28, 2023 in New York City. Details are as follows:

2023 Cantor Fitzgerald Global Healthcare Conference

Panel Presentation Date and Time: Tuesday, September 26, 2023, from 10:30 am – 11:00 am ET

Location: InterContinental Barclay Hotel

A live webcast of the panel presentation can be accessed from the Investors section of the Athira website at . An archived replay of the webcasts will be available for at least 30 days following the event.

About Athira Pharma, Inc.

Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological disease by advancing its pipeline of therapeutic candidates targeting the HGF/MET neurotrophic system for Alzheimer’s and Parkinson’s disease, Dementia with Lewy bodies, and amyotrophic lateral sclerosis. For more information, visit . You can also follow Athira on ,  and @athirapharma on , formerly known as , and .

Investor & Media Contact:

Julie Rathbun

Athira Pharma



206-769-9219



EN
19/09/2023

Underlying

ATHAAthira Pharma

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Athira Pharma

 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 202...

Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025 BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented results from its Phase 1 clinical trial of ATH-1105 in healthy volunteers at the ALS Nexus 2025 conference in Dallas, Texas. ALS Nexus convenes leading experts from the ALS community, including researchers, healthcare professionals, advocates and individuals living with amyotrophic lateral ...

August 14, 2025 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Reports Second Quarter 2025 Financial Results and Provid...

Athira Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development BOTHELL, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended June 30, 2025,...

August 7, 2025 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Tri...

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development On-track to enable initiation of a clinical trial in ALS patients in late 2025 BOTHELL, Wash., May 13, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to r...

May 13, 2025 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Reports First Quarter 2025 Financial Results and Pipelin...

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable dosing ALS patients in late 2025 BOTHELL, Wash., May 09, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ...

May 9, 2025 1 EN
 PRESS RELEASE
Free
ATHA ATHIRA PHARMA

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline an...

Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS) On-track to enable dosing ALS patients in 2025 BOTHELL, Wash., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2024, and provided recent pipeline and bus...

February 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch